These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32976026)

  • 1. Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.
    Pau AK; Aberg J; Baker J; Belperio PS; Coopersmith C; Crew P; Grund B; Gulick RM; Harrison C; Kim A; Lane HC; Masur H; Sheikh V; Singh K; Yazdany J; Tebas P;
    Ann Intern Med; 2021 Jan; 174(1):93-95. PubMed ID: 32976026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convalescent blood plasma (CBP) donated by recovered COVID-19 patients - A comment.
    Lung T; Sakem B; Risch M; Nydegger U
    Transfus Apher Sci; 2021 Jun; 60(3):103108. PubMed ID: 33678561
    [No Abstract]   [Full Text] [Related]  

  • 3. Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019.
    Hartog N; Holsworth A; Rajasekaran S
    Ann Allergy Asthma Immunol; 2021 Feb; 126(2):122-123. PubMed ID: 33161152
    [No Abstract]   [Full Text] [Related]  

  • 4. Emergency Approvals for COVID-19: Evolving Impact on Obligations to Patients in Clinical Care and Research.
    Lynch HF; Bateman-House A; Joffe S
    Ann Intern Med; 2021 Feb; 174(2):256-257. PubMed ID: 33136427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations on the use of COVID-19 Convalescent Plasma to Treat Immunocompromised Patients.
    Franchini M; Casadevall A; Senefeld JW; Joyner MJ; Sullivan DJ; Focosi D
    Semin Thromb Hemost; 2024 Jun; 50(4):648-653. PubMed ID: 37984358
    [No Abstract]   [Full Text] [Related]  

  • 6. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
    Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
    Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convalescent Plasma: Education and Administration Implications.
    Martin JC
    Clin J Oncol Nurs; 2021 Feb; 25(1):28-32. PubMed ID: 33480877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The resurgence of convalescent plasma therapy.
    The Lancet Haematology
    Lancet Haematol; 2020 May; 7(5):e353. PubMed ID: 32359447
    [No Abstract]   [Full Text] [Related]  

  • 9. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report.
    Omrani AS; Zaqout A; Baiou A; Daghfal J; Elkum N; Alattar RA; Bakdach D; Abusriwil H; Mostafa AM; Alhariri B; Ambra N; Khatib M; Eldeeb AM; Merenkov Z; Fawzi Z; Hmissi SM; Hssain AA; Coyle PV; Alsoub H; Almaslamani MA; Alkhal A
    J Med Virol; 2021 Mar; 93(3):1678-1686. PubMed ID: 32965715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19: benefits and risks of passive immunotherapeutics.
    Gupta A; Karki R; Dandu HR; Dhama K; Bhatt ML; Saxena SK
    Hum Vaccin Immunother; 2020 Dec; 16(12):2963-2972. PubMed ID: 32962524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thinking more about therapy with convalescent plasma for COVID-19 patients.
    Han G; Zhou YH
    Hum Vaccin Immunother; 2020 Nov; 16(11):2601-2603. PubMed ID: 32643512
    [No Abstract]   [Full Text] [Related]  

  • 12. Convalescent Plasma Therapy for Corona Virus Disease 2019: a Long Way to Go but Worth Trying.
    Yoo JH
    J Korean Med Sci; 2020 Apr; 35(14):e150. PubMed ID: 32281318
    [No Abstract]   [Full Text] [Related]  

  • 13. Google Trends demonstrate public interest in COVID-19 convalescent plasma therapy.
    Adkins BD; Booth GS
    J Clin Apher; 2021 Jun; 36(3):492-493. PubMed ID: 33340373
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of immunocompromised COVID-19 patients with convalescent plasma.
    Fung M; Nambiar A; Pandey S; Aldrich JM; Teraoka J; Freise C; Roberts J; Chandran S; Hays SR; Bainbridge E; DeVoe C; Roque Gardner A; Yokoe D; Henrich TJ; Babik JM; Chin-Hong P
    Transpl Infect Dis; 2021 Apr; 23(2):e13477. PubMed ID: 32989856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-SARS-CoV-2 hyperimmune plasma workflow.
    Annamaria P; Eugenia Q; Paolo S
    Transfus Apher Sci; 2020 Oct; 59(5):102850. PubMed ID: 32540345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time.
    Prus K; Alquist CR; Cancelas JA; Oh D
    Transfusion; 2021 Feb; 61(2):651-654. PubMed ID: 33616966
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma.
    Kostin AI; Lundgren MN; Bulanov AY; Ladygina EA; Chirkova KS; Gintsburg AL; Logunov DY; Dolzhikova IV; Shcheblyakov DV; Borovkova NV; Godkov MA; Bazhenov AI; Shustov VV; Bogdanova AS; Kamalova AR; Ganchin VV; Dombrovskiy EA; Volkov SE; Drozdova NE; Petrikov SS
    Vox Sang; 2021 Jul; 116(6):665-672. PubMed ID: 33734455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study.
    Wu Y; Hong K; Ruan L; Yang X; Zhang J; Xu J; Pan S; Ren L; Chen L; Huang C; Shang Y
    Virol Sin; 2020 Dec; 35(6):768-775. PubMed ID: 32865701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 Convalescent Plasma: from donation to treatment - A Systematic Review & Single Center Experience.
    Fabricius MM; Dandachi D
    Mo Med; 2021; 118(1):74-80. PubMed ID: 33551490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.